A first preliminary study using three mice per group was performed to analyze the impact of single targeting VEGF and Ang-2 using specific antibodies compared to co-targeting mediated by the bispecific CrossMab in the DLD1 colorectal carcinoma xenograft model (Figure 1). This evidence concerns the gene VEGFA and colorectal carcinoma.